Xerimis Partners With Area Europe on State-of-the-Art Facility in the Netherlands
We’re thrilled to be working alongside Area Europe, a UK-based construction firm specializing in workplaces, on the design and fit-out of our environmentally sustainable facility in the Netherlands. The 45,000-square-foot site marks the new location for our next global depot, enabling us to increase operations in alignment with the growing needs of our clients.
EU Clinical Trials Regulation Is Here
The EU Clinical Trials Regulation (CTR) has been in the works since 2014, but now that it’s actually here, what are the basics you need to know?
Decentralized Clinical Trials: Advancing the Trend Toward Patient-Centric Studies
Clinical trials have traditionally revolved around specific clinical sites where study participants visit and the bulk of trial activities take place. Designed to increase patient convenience and bolster the enrollment process, decentralized clinical trials (DCTs) use a virtual-first approach to bring the study to patients, wherever they are.
Major Expansion Highlights Xerimis’ 20th Anniversary
As we enter our 20th year in business, Xerimis is proud to announce major expansion at our US headquarters as well as expansion in Europe. These efforts will increase our storage and service capabilities, while enabling us to stay focused on our core values of quality, flexibility, reliability, and responsiveness.
Xerimis: Proudly Celebrating 20 Years in Clinical Supplies
It started with business plans that took a surprising turn in order to serve a highly specialized industry. Here’s a brief look at the history of Xerimis, what makes us unique, and how we’ve evolved over the years.
Introducing APEX for Optimized Clinical Supply Management
Clinical trials are full of unknowns. Trials hinge on detailed planning in countless areas under the clinical supply management (CSM) umbrella: sourcing and procurement, temperature monitoring, logistics management, supplies forecasting, import regulations, and more. Given the potential for supply chain unknowns to delay or derail studies, sponsor companies—particularly those new to the clinical trial scene—can benefit from outsourcing its CSM to experts.